Antidepressant Withdrawal vs Relapse: How to Tell the Difference

How to Tell Antidepressant Withdrawal From Relapse

Antidepressant withdrawal usually starts within hours or days of a dose reduction, brings physical symptoms such as dizziness and electric shock sensations, and settles fast when the dose is reinstated with a clinician. Relapse builds over weeks to months and resembles the original episode, though withdrawal can also be delayed.

Consider someone who reduces their dose by half, feels steady for three days, and then wakes up dizzy, nauseated, tearful and jolted by strange electrical sensations behind the eyes. At the next appointment they are told the depression has come back and the dose should go up. Sometimes that is right. Often it is not. The distinction matters, because one answer leads to a slower, supported reduction and the other leads to years more medication that may never have been needed.

image: a clinician and patient looking together at a symptom diary on a tablet, warm daylight, real photography

Why Withdrawal Is So Often Read as Relapse

Withdrawal from an antidepressant can include low mood, anxiety, panic, irritability, insomnia and intrusive thoughts. Those are also the symptoms that brought most people to the medication in the first place, so both patient and clinician reach for the familiar explanation. The Maudsley Deprescribing Guidelines describe this misreading as one of the most consequential errors in deprescribing, because it can lead to long term reinstatement of a drug the person was trying to leave, and to the belief that they have a more severe and more permanent condition than they do (Horowitz & Taylor, 2024).

Feeling depressed or anxious is real, and relapse is real. The point is not that every symptom appearing after a dose change is withdrawal. It is that the two have different signatures, and those signatures can be read.

The Three Markers That Separate Withdrawal From Relapse

1. Timing in Relation to the Dose Change

Withdrawal symptoms typically appear within hours or days of a missed dose, a reduction or a stop. Relapse usually does not. NICE's 2022 depression guideline tells clinicians that relapse does not ordinarily happen as soon as someone stops or lowers an antidepressant, while withdrawal symptoms commonly follow a dose change closely (NICE, 2022). Timing is not a clean rule, though. Symptoms can also arrive weeks or months after a reduction or a last dose, which is called delayed onset withdrawal and is described in the section below (Fava et al., 2015; Horowitz & Taylor, 2022, 2024). Timing is still the first question worth asking: what changed, and when.

2. Physical and Sensory Signposts

Primary depression does not usually produce dizziness, vertigo, electric shock sensations often called brain zaps, nausea, flu-like aching, sweating, tinnitus, heightened sensitivity to light and sound, or akathisia, the intense inner restlessness that can feel like terror. When physical symptoms of this kind sit alongside the psychological ones, withdrawal becomes the more parsimonious explanation (Horowitz & Taylor, 2024). Psychological symptoms can also be discriminating when they are qualitatively new. A person treated for flat, low mood who now has surging panic and agitation is describing something different from their original episode, not a worse version of it.

3. Response to Reinstatement

Acute withdrawal symptoms tend to improve quickly when the previous dose is restored, sometimes within hours, and that speed is one of the clearest distinguishing features (Horowitz & Taylor, 2024). A depressive episode does not resolve overnight on a single dose. As Dr. Bryan Shapiro, Senior Consultant at Outro Health, puts it, "antidepressant withdrawal symptoms reliably and rapidly abate with the reinstatement of the dose" (APA Medical Mind podcast, 2025). Reinstatement is a clinical decision made with a clinician, not something to try alone, and it appears to work less predictably when it is delayed for months after symptoms begin (Horowitz & Taylor, 2024).

Delayed Onset Withdrawal: When Symptoms Arrive Weeks Later

Withdrawal does not always keep to the few days most clinical guidelines describe. Symptoms can first appear weeks, and sometimes months, after a dose reduction or the last dose. This is often called delayed onset withdrawal. It is best known with Prozac (fluoxetine), whose active metabolite norfluoxetine stays in the body for weeks, so the drug effect falls slowly and the symptoms turn up late. It also happens with shorter-acting SSRIs and SNRIs, possibly because drug levels in the brain take longer to adjust than levels in the blood (Fava et al., 2015; Horowitz & Taylor, 2022, 2024).

This is where a lot of the misreading happens. Symptoms that show up six weeks after a reduction rarely get called withdrawal; they get called relapse, or a new illness. Delayed onset also changes pacing. Horowitz and Taylor (2019) suggest waiting about four weeks after an SSRI reduction before judging its effects, and the Maudsley Deprescribing Guidelines suggest gaps of six to eight weeks between some fluoxetine reductions for the same reason (Horowitz & Taylor, 2024). As with every part of this, timing, severity and duration are highly individual: mild for days or weeks for some people, prolonged for others, with longer use, past withdrawal and faster reductions raising the risk (Davies & Read, 2019; Horowitz et al., 2023).

Side by Side

Why "Discontinuation Syndrome" Is the Wrong Name

Much of the confusion is built into the vocabulary. The more accurate and honest term is antidepressant withdrawal. "Discontinuation syndrome" is a pharmaceutical industry euphemism that shifts responsibility for the difficulty of stopping from the drug to the patient, and it primes people to expect something mild and brief. When a person then experiences something that is neither mild nor brief, the euphemism leaves only one explanation available: the illness must have returned.

What the Nervous System Is Actually Doing

Taking an antidepressant daily for months or years changes how the brain operates in the presence of the drug. Those adaptations do not reverse the moment the drug is reduced. Withdrawal is the gap between a lowered drug level and a nervous system that has not yet adjusted, which is why symptoms cluster around dose changes rather than appearing at random.

The size of that gap is not proportional to the milligrams removed. PET imaging shows that SSRIs occupy roughly 80% of serotonin transporters at their minimum therapeutic doses, with occupancy rising steeply at low doses and flattening at higher ones (Meyer et al., 2004). Because each milligram has a larger effect at the bottom of the dose range than at the top, equal sized cuts produce progressively larger jolts as the dose gets smaller, and reductions that get progressively smaller produce roughly even steps in drug effect (Horowitz & Taylor, 2019; Dr. Horowitz is Outro Health's clinical co-founder). That pharmacology is explained in more depth in our guide to what hyperbolic tapering is and why the last milligrams matter.

Half-Life Is Not the Whole Story

Drugs with shorter half-lives, such as Paxil (paroxetine) and Effexor (venlafaxine), tend to produce faster and sharper acute withdrawal, and a longer half-life can blunt or delay it. But the drug clearing the bloodstream is not the same as the brain's adaptations reversing. Symptoms can persist, or begin, well after the medication itself is gone, because the brain is still adjusting to the absence of the medication. We look at those recovery timelines in more detail in does your brain go back to normal after antidepressants.

How Common Withdrawal Is, and How Long It Lasts

Severity, symptom pattern and duration are highly individual. Some people notice mild effects for a few days or weeks. Many others have prolonged symptoms that are mistaken for relapse. A 2019 systematic review found that across 14 studies, an average of 56% of people who stopped antidepressants experienced withdrawal effects, with a range from 27% to 86% (Davies & Read, 2019). In a 2025 survey of 310 NHS primary-care patients who had tried to stop an antidepressant, 79% reported withdrawal symptoms, 45% rated them moderately severe or severe, 20% had symptoms lasting more than three months and 10% for more than a year (Horowitz et al., 2025). That survey had an 18% response rate and relies on retrospective self-report, so the figures describe the people who answered rather than every patient.

Risk is not evenly distributed. Longer time on the drug, SNRIs and paroxetine, a shorter half-life, previous withdrawal experience and stopping quickly are all associated with higher risk, with higher dose showing a weaker association (Horowitz et al., 2023). NICE notes that withdrawal can sometimes be severe and last several weeks or occasionally several months, while also noting that most people stop successfully (NICE, 2022). Both things are true, and neither tells an individual which group they are in. The stepwise pattern of symptom onset is set out in our overview of the phases of SSRI withdrawal.

If symptoms include thoughts of suicide, agitation that feels unbearable, or you feel unsafe, contact emergency services or call or text 988 in the US, and see our crisis resources. Do not stop an antidepressant suddenly without clinical support.

Relapse Is Still Possible, and That Is Not a Reason to Panic

Genuine relapse happens, and a careful clinician stays alert to it. It is worth holding two facts alongside each other.

First, symptoms that come back months after stopping, with the person's own familiar pattern and no physical signposts, may well be relapse, although delayed onset withdrawal can also begin weeks or months after a reduction or a last dose, so timing on its own does not settle the question.

Second, most people recover from depression within a year, including those with severe episodes (Whiteford et al., 2013), so a difficult period after stopping is not automatic evidence of a permanent, medication-dependent condition. It is also worth knowing that what gets recorded as a pattern of recurrent episodes sometimes turns out to be tolerance to the drug or a failed, too-fast taper. Clinical guidelines describe treatment durations after a first or a recurrent episode, and how long any individual takes a medication is a decision for that person and their clinician.

What a Supported Reduction Looks Like in Shape

Reading the difference between withdrawal and relapse is easier when reductions are small enough that any reaction is interpretable. The Maudsley Deprescribing Guidelines describe tapering as a repeated cycle: an initial reduction sized to the person's estimated withdrawal risk, monitoring of the symptoms it causes, then sizing the next reduction by how tolerable the last one was, continuing until the dose is small enough that the final step to zero is no larger, in receptor-occupancy terms, than the steps already tolerated (Horowitz & Taylor, 2024).

Peer-led tapering communities have arrived at reductions of roughly a tenth of the most recent dose, each one smaller than the last, which closely approximates the schedules derived from occupancy data (Horowitz & Taylor, 2024).

Those proportions are illustrative, not a plan. A clinician individualizes the size and spacing, doses are often paced by how a person feels rather than by the calendar, and the final doses are usually far smaller than the lowest available tablet, which is why liquid or compounded forms are used. Our overview of SSRI taper schedules goes through the shape in more detail.

Who This Distinction Matters Most For

• People who have been on an antidepressant for years and are noticing symptoms within days of a dose change
• People whose symptoms after a dose change include physical or sensory features they did not have before
• People who tried to stop before, were told it was relapse, and went back up in dose
• People who feel steady on their medication and are not considering a change, for whom this is background reading rather than a decision

Conclusion

Withdrawal and relapse can look alike on the surface and behave very differently underneath. Timing in relation to the dose change, the presence of physical and sensory symptoms, and the speed of response to reinstatement are the three markers that do most of the work. None of them is decided by how anxious or low a person feels, which is exactly why the two get confused. Bringing a dated record of dose changes and symptoms to a clinician turns a vague conversation into a readable one, and makes a slower, symptom-led reduction possible for anyone who decides, with their clinician, that stopping is what they want.

If You Are Trying to Work Out Which One You Are Having

Outro Health is a telehealth clinic for people who want to come off antidepressants with clinical support. Clinicians trained in deprescribing take over the prescription during the taper, monitor withdrawal symptoms between visits, work with compounding pharmacies when doses smaller than the lowest tablet are needed, and are trained to distinguish withdrawal from relapse rather than assuming one or the other. Outro Health's tapering program is currently available to patients in more than a dozen states, including California, Florida, New York, Texas and more. If you would like to find out whether an evaluation with an Outro Health clinician fits your situation, you can read about the Taper Management Program.